Analysts See $-0.06 EPS for ArQule, Inc. (ARQL)

April 26, 2018 - By Graig Alexander

ArQule, Inc. (NASDAQ:ARQL) Logo

Analysts expect ArQule, Inc. (NASDAQ:ARQL) to report $-0.06 EPS on May, 2.They anticipate $0.05 EPS change or 45.45 % from last quarter’s $-0.11 EPS. After having $-0.09 EPS previously, ArQule, Inc.’s analysts see -33.33 % EPS growth. The stock increased 4.07% or $0.11 during the last trading session, reaching $2.81. About 471,223 shares traded. ArQule, Inc. (NASDAQ:ARQL) has risen 180.00% since April 26, 2017 and is uptrending. It has outperformed by 168.45% the S&P500.

ArQule, Inc. (NASDAQ:ARQL) Ratings Coverage

Among 5 analysts covering Arqule (NASDAQ:ARQL), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Arqule had 5 analyst reports since December 14, 2017 according to SRatingsIntel. The stock of ArQule, Inc. (NASDAQ:ARQL) earned “Buy” rating by Leerink Swann on Thursday, April 5. The rating was upgraded by Needham on Thursday, December 14 to “Buy”. The company was maintained on Monday, February 12 by B. Riley & Co. The rating was initiated by FBR Capital with “Buy” on Friday, February 2.

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company has market cap of $244.78 million. The Company’s lead product candidate is tivantinib , a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer. It currently has negative earnings. The company's clinical-stage products include ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor family Phase II clinical trial for patients with intrahepatic cholangiocarcinoma and in Phase Ib for multiple oncology indications; ARQ 092, an inhibitor of the AKT serine/threonine kinase in Phase I clinical trials for multiple oncology indications; ARQ 751, a next-generation inhibitor of AKT in Phase I clinical trial for solid tumors; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is Phase 1b clinical trial used as a promoter of NQo1-mediated programmed cancer cell death.

ArQule, Inc. (NASDAQ:ARQL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.